006), whereas both IGF1 receptor (IGF1R) and IGF binding protein 2 (IGFBP2) mRNAs were reduced in schizophrenia compared with controls (P ? .02). EGF, FGF, and BDNF family member expression were all unchanged in both psychiatric disorders compared with controls. IGF1 expression positively predicted neuronal progenitor and immature neuron marker mRNAs (P ? .01). IGFBP2 expression positively predicted neural stem cell and neuronal progenitor marker mRNAs (P ? .001). These findings provide the first molecular evidence of decreased IGF1, IGF1R, and IGFBP2 mRNA expression in the subependymal zone in psychiatric disorders, which may potentially impact neurogenesis in schizophrenia and bipolar disorder.To build a prediction model for uveitis in children with JIA for use in current clinical practice.
Data from the international observational Pharmachild registry were used. Adjusted risk factors as well as predictors for JIA-associated uveitis (JIA-U) were determined using multivariable logistic regression models. The prediction model was selected based on the Akaike information criterion. Bootstrap resampling was used to adjust the final prediction model for optimism.
JIA-U occurred in 1102 of 5529 JIA patients (19.9%). The majority of patients that developed JIA-U were female (74.1%), ANA positive (66.0%) and had oligoarthritis (59.9%). JIA-U was rarely seen in patients with systemic arthritis (0.5%) and RF positive polyarthritis (0.2%). Independent risk factors for JIA-U were ANA positivity [odds ratio (OR) 1.88 (95% CI 1.54, 2.30)] and HLA-B27 positivity [OR 1.48 (95% CI 1.12, 1.95)] while older age at JIA onset was an independent protective factor [OR 0.84 (9%% CI 0.81, 0.87)]. On multivariable analysis, the combination of age at JIA onset [OR 0.84 (95% CI 0.82, 0.86)], JIA category and ANA positivity [OR 2.02 (95% CI 1.73, 2.36)] had the highest discriminative power among the prediction models considered (optimism-adjusted area under the receiver operating characteristic curve = 0.75).
We developed an easy to read model for individual patients with JIA to inform patients/parents on the probability of developing uveitis.
We developed an easy to read model for individual patients with JIA to inform patients/parents on the probability of developing uveitis.Epilepsy is a heterogenous group of disorders defined by recurrent seizure activity due to abnormal synchronized activity of neurons. A growing number of epilepsy cases are believed to be caused by genetic factors and copy number variants (CNV) contribute to up to 5% of epilepsy cases. However, CNVs in epilepsy are usually large deletions or duplications involving multiple neurodevelopmental genes. In patients who underwent seizure focus resection for treatment-resistant epilepsy, whole genome DNA methylation profiling identified 3 main clusters of which one showed strong association with receptor tyrosine kinase (RTK) genes. We identified focal copy number gains involving epidermal growth factor receptor (EGFR) and PDGFRA loci. The dysplastic neurons of cases with amplifications showed marked overexpression of EGFR and PDGFRA, while glial and endothelial cells were negative. https://www.selleckchem.com/products/e1210.html Targeted sequencing of regulatory regions and DNA methylation analysis revealed that only enhancer regions of EGFR and gene promoter of PDGFRA were amplified, while coding regions did not show copy number abnormalities or somatic mutations. Somatic focal copy number gains of noncoding regulatory represent a previously unrecognized genetic driver in epilepsy and a mechanism of abnormal activation of RTK genes. Upregulated RTKs provide a potential avenue for therapy in seizure disorders.The year-round RSV circulation in tropical regions leads to different transmission patterns and burden of disease among infants born very preterm.
We conducted a retrospective cohort study to estimate the effectiveness of palivizumab in preventing RSV hospitalization among infants born &lt;32 weeks gestation at 6 and 12 months after discharge in our tropical setting.
A total of 109 (26.3%) infants received palivizumab at discharge, out of 415 who were eligible. All patients received at least 4 doses, with 105 infants (96.3%) completing 5 doses. Within one-year post-discharge, there were 35 RSV-associated admissions (3 palivizumab vs 32 non-palivizumab, 2.8% vs 10.5%, p=0.02). After adjusting for confounders, the effectiveness of palivizumab against RSV hospitalisation was estimated to be 90% (95%CI 10% to 99%) up to 6-months post-discharge. The median length of time to RSV hospitalization was shorter in the non-palivizumab compared to the palivizumab group, 155 days (15, 358) vs 287 days (145, 359), p=0.1. Five infants (14.3%), all from the non-palivizumab group, required admission to the intensive care unit.
In our setting with year-round RSV circulation, palivizumab prophylaxis was effective in reducing RSV hospitalization among high-risk preterm infants &lt;32 weeks gestation within the first 6 months post-discharge.
In our setting with year-round RSV circulation, palivizumab prophylaxis was effective in reducing RSV hospitalization among high-risk preterm infants less then 32 weeks gestation within the first 6 months post-discharge.To compare an intermittent audit method vs a daily documentation method with regard to the number of interventions documented by clinical pharmacists in the hospital setting.
A 2-phase pre-post cohort study was conducted at an academic hospital to compare numbers and types of pharmacist interventions documented over an 18-month period before implementation of a daily documentation method (the "pre-phase" period) and during the 6 months after implementation (the "post-phase" period). During the pre-phase period (January 2018 to July 2019), pharmacists prospectively documented interventions on specific audit days. The audit days occurred at approximately monthly intervals. During the post-phase period (July 2019 to March 2020) pharmacists used electronic medical record tools to document interventions daily. The primary outcome was the total number of interventions per day. Values for the pre- and post-phase periods were compared using an unpaired Student t test and through interrupted time series analysis.
There were a total of 3,628 interventions (on 14 intermittent audit days) during the pre-phase period and 9,300 interventions (on 163 continuous days) in the post-phase period.